Michael L. Meyers - Feb 2, 2022 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
SVP, Chief Medical Officer
Signature
/s/ Michael A. Metzger, Attorney-in-Fact
Stock symbol
SNDX
Transactions as of
Feb 2, 2022
Transactions value $
$295,193
Form type
4
Date filed
2/3/2022, 04:31 PM
Previous filing
Jan 3, 2022
Next filing
Oct 6, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Other $21.2K +1.71K +7.95% $12.39 23.3K Jan 31, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Award $274K +17.4K $15.79 17.4K Feb 2, 2022 Common Stock 17.4K $15.79 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,715 shares by the Reporting Person on 1/31/22 pursuant to the Issuer's Employee Stock Purchase Plan.
F2 1/23rd of the shares subject to the option shall vest monthly over a two-year period.